Sanofi Consumer Healthcare India Limited has published its postal ballot notice in newspapers on March 24, 2026, confirming the successful dispatch to shareholders seeking approval for material related party transactions and key remuneration matters. The company filed the publication notice with BSE Limited and National Stock Exchange of India Limited, completing regulatory compliance requirements.

Postal Ballot Publication Details

The company published the postal ballot notice in two newspapers to ensure widespread shareholder awareness:

Shareholder Approval Resolutions

The postal ballot seeks shareholder approval for four ordinary resolutions covering significant corporate matters:

Related Party Transaction Approvals

The company is seeking approval for significant related party transactions with two group entities during the financial year ending December 31, 2026:

Voting Process and Timeline

The postal ballot follows a comprehensive electronic voting process managed by National Securities Depository Limited (NSDL):

Scrutinizer Appointment

The Board of Directors has appointed qualified scrutinizers to ensure fair and transparent voting:

Remuneration Matters

The postal ballot includes important remuneration decisions affecting company leadership:

Non-Executive Director Commission

Shareholders will vote on extending authorization for paying commission to Non-Executive Directors for five years from January 1, 2025 to December 31, 2029, maintaining the current structure of maximum 1% of net profits plus sitting fees.

Managing Director Incentive Plan

The company seeks approval for Mr. Himanshu Bakshi's participation in the Global Long Term Incentive Plan, enhancing the existing compensation framework to align with international best practices.

Regulatory Compliance

All proposed transactions comply with SEBI Listing Regulations and have received prior Audit Committee approval. The transactions are structured to be conducted at arm's length basis and in the ordinary course of business. Related parties will abstain from voting on respective resolutions as per regulatory requirements.

Shareholders can access detailed information on the company's website at www.sanofi.in and NSDL's e-voting portal for comprehensive voting procedures and resolution details.

Source: None/Company/INE0UOS01011/3503441a-9928-48be-aba6-77161e590388.pdf

Sanofi Consumer Healthcare India Limited has submitted its Annual Secretarial Compliance Report for the financial year ended 31st December 2025 to the stock exchanges, fulfilling its regulatory obligations under SEBI guidelines. The company filed the mandatory report with both BSE Limited and National Stock Exchange of India Limited on 1st March 2026, demonstrating its commitment to corporate governance and regulatory compliance.

Regulatory Compliance Overview

The Annual Secretarial Compliance Report was prepared by BNP & Associates, Company Secretaries, covering the company's adherence to statutory provisions and corporate governance practices. The comprehensive review examined the company's compliance with various SEBI regulations and guidelines throughout the financial year 2025.

Key Regulatory Areas Examined

The secretarial audit covered multiple critical areas of regulatory compliance. BNP & Associates examined the company's adherence to Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company maintained a Structured Digital Database as required under the insider trading regulations.

Additionally, the review encompassed compliance with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, along with associated circulars and guidelines.

Comprehensive Compliance Assessment

The secretarial compliance report evaluated 13 specific areas of regulatory requirements, with the company achieving full compliance across all parameters. Key areas of assessment included performance evaluation of the Board and Independent Directors, related party transaction approvals, and timely disclosure of events under Regulation 30.

Clean Compliance Record

The report confirmed that no violations or deviations were identified during the review period. The company maintained a clean record with no actions taken by SEBI or stock exchanges against the entity, its promoters, or directors. No statutory auditor resignations occurred during the financial year, and no additional non-compliances were observed beyond those reported.

Corporate Structure and Operations

Sanofi Consumer Healthcare India Limited operates with its registered office at Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra. As a subsidiary of a company incorporated outside India, the entity follows a calendar year as its financial year to facilitate consolidation with its holding company, having obtained requisite approval under Section 2(41) of the Companies Act, 2013.

The company secretary and compliance officer, Nikunj Kumar Savaliya, digitally signed and submitted the compliance report, ensuring proper documentation and regulatory adherence. The comprehensive assessment by BNP & Associates validates the company's robust compliance framework and commitment to regulatory excellence throughout the financial year 2025.